Photo: Fred Hutch
Education, Training, Board Certifications
- M.D., The Ohio State University
- Residency, The Ohio State University
- Fellowship, UW/Fred Hutch
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Hematopoietic stem cell transplantation
- Multiple myeloma
- Waldenström’s Macroglobulinemia
- Fred Hutchinson Cancer Center - Faculty & Lab
- University of Washington
- Fred Hutchinson Cancer Center - Provider
Research and/or clinical interests
Dr. Damian Green develops new immunotherapies that harness the power of the immune system to treat and ultimately eradicate multiple myeloma and lymphoma. A major research focus is radioimmunotherapy, in which radioactive particles are linked to cancer-targeting molecules called antibodies to deliver deadly radiation straight to cancer cells while sparing healthy tissues. Dr. Green also studies a type of immunotherapy called bispecific antibody therapy in which a two-pronged antibody brings together cancer-killing immune cells and cancer cells. Another major focus of his work is the development and clinical evaluation of a form of genetically engineered T-cell therapy (called CAR T-cell therapy) for patients with myeloma.
Dr. Green’s research is supported by three competitive federal grants on which he is lead investigator and through a variety of non-profit research foundation initiatives focused on improving stem cell transplant outcomes, delivering targeted radiation to tumor cells and improving the efficacy of chimeric antigen receptor (CAR) T-cell therapy. He is the principal investigator on numerous clinical trials, including studies to evaluate CAR T-cell therapy in multiple myeloma. Dr. Green is also a lead investigator on a multi-center network grant through the Multiple Myeloma Research Foundation (MMRF) designed to define optimal tumor and host signatures for immunotherapy of multiple myeloma. He is also co-leader on an initiative with the Allen Institute for Immunology focused on characterizing the dysregulation of immune function in multiple myeloma. In addition, he is co-investigator on over 20 clinical trials for patients with multiple myeloma or lymphoma.